Table 1.
Prostaglandin ng/mg protein |
Baseline change (%)† |
|||
---|---|---|---|---|
Control | FAP | FAP & SUL | ||
PGD2 | 1.541 ± 0.461 | 1.136 ± 0.182 | 0.729 ± 0.450c | −38.8 |
PGE2 | 5.355 ± 1.015 | 4.832 ± 0.454 | 2.930 ± 1.820bc | −32.3 |
PGF2a | 3.345 ± 0.791 | 2.917 ± 0.881 | 1.618 ± 0.888bc | −43.6 |
TXB2 | 0.945 ± 0.042 | 1.673 ± 0.329a | 1.005 ± 0.643b | −45.2 |
6KPGF1a | 0.960 ± 0.482 | 1.184 ± 0.108 | 0.567 ± 0.307bc | −49.5 |
Results are mean ± SD. FAP is familial adenomatous polyposis; FAP & SUL is FAP patients treated with sulindac.
P = 0.016 FAP compared to control
P = 0.05 FAP compared with FAP treated with sulindac
P = 0.05 FAP treated with sulindac compared to control.
Percent change from baseline in patients before and after sulindac treatment.